Atlas Trials

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Clinical trial NCT00496431 · TERMINATED

Trial details

NCT number
NCT00496431
Sponsor
Italfarmaco
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hodgkin's Lymphoma
Start date
2007-05-01
Primary completion
2009-03-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.